Yervoy (ipilimumab) - BMS
ABP 206 (nivolumab biosimilar) - Amgen
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Nivocad (nivolumab biosimilar) - Biocad
Cabometyx (cabozantinib tablet) - Exelixis
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 10, 2026 - P2 | N=66 | Active, not recruiting | Sponsor: National Cancer Institute LAO | Trial completion date: May 2026 ➔ May 2028 | Trial primary completion date: May 2026 ➔ May 2028 
Trial completion date • Trial primary completion date • Tumor mutational burden • Leiomyosarcoma • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma
http://clinicaltrials.gov/ct2/show/NCT05836571
 
Oct 10, 2026
 
Prev Next